Immunotherapy and the Management of Allergies: An Overview of Monoclonal Antibody Therapy and Allergen Immunotherapy

Gulakavarapu S V S Manmohit | Narapaneni Sravanthi ^[4] | Praneeth Ulavala ^[14] | S. Chandrababu ^[3]

Abstract: Allergies affect a significant portion of the global population, causing symptoms ranging from mild discomfort to severe anaphylactic reactions. Conventional treatments like antihistamines and corticosteroids offer only temporary relief and fail to address the underlying immune system dysfunction. This article provides an overview of two promising immunotherapy approaches for managing allergies: allergen immunotherapy (AIT) and monoclonal antibody therapy. Around 40% of the world's population grapples with allergies, leading to sleep disturbances, work or school absenteeism, and reduced productivity, negatively impacting quality of life. AIT, commonly known as allergy shots, involves gradual exposure to allergen extracts to build tolerance, effectively altering the immune response and reducing symptom frequency and severity. It typically consists of a build-up phase and a maintenance phase, requiring regular allergen administration. Monoclonal antibody therapy, administered via injection or nasal spray, targets the immune response to allergens, offering relief for severe allergies by diminishing symptom frequency and intensity. Both forms of immunotherapy have demonstrated efficacy in improving patients' quality of life, with generally mild and brief side effects. In conclusion, immunotherapy stands as an effective option for allergy management, addressing the root cause and potentially reducing symptoms over time. Individuals with allergies should consult their healthcare providers to determine if immunotherapy is a suitable treatment option.

Keywords: Immunotherapy, Allergen immunotherapy, Monoclonal antibody therapy, Allergy management

Edition: Volume 12 Issue 9, September 2023,

Pages: 1051 - 1053